Kidney cancer, also known as renal cell carcinoma, is a type of cancer that begins in the renal cells of the kidney. Over the past few decades, tremendous advancements have been made in developing targeted drugs to treat kidney cancer. These new drugs have led to significantly higher survival and remission rates for patients. Here is an overview of some of the major kidney cancer drugs available today and the progress being made.

Tyrosine Kinase Inhibitors

One of the major breakthroughs in kidney cancer treatment has been the development of tyrosine kinase inhibitors (TKIs). Kidney Cancer Drugs  TKIs work by blocking enzymes called tyrosine kinases which help cancer cells grow and spread. Some of the main TKIs used for kidney cancer include:

- Sunitinib (Sutent): Sunitinib was one of the earliest TKIs developed specifically for kidney cancer. It works by blocking several tyrosine kinases to inhibit tumor growth and angiogenesis (formation of new blood vessels). Sunitinib became the standard first-line treatment option for advanced or metastatic kidney cancer due to its effectiveness in improving survival rates.

Get more insights on This Topic- Kidney Cancer Drugs